Drugs / Silybinin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07561892 | Apr 2022 → Dec 2026 expected | acute myeloid leukemia, chemotherapy-induced toxicity | Fujian Medical University Union Hospital | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Silybinin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07561892 ↗ |